Novel semicarbazides and ureas of primaquine with bulky aryl or hydroxyalkyl substituents: Synthesis, cytostatic and antioxidative activity

Novel primaquine semicarbazides 7a–l and ureas 9a–g with modified benzhydryl, trityl, phenyl or hydroxyalkyl substituents were prepared and evaluated for cytostatic and antioxidative activities. Two synthetic approaches for preparation of the title semicarbazides were applied, both having certain ad...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of medicinal chemistry 2014-10, Vol.86, p.502-514
Hauptverfasser: Pavić, K., Perković, I., Cindrić, M., Pranjić, M., Martin-Kleiner, I., Kralj, M., Schols, D., Hadjipavlou-Litina, D., Katsori, A.-M., Zorc, B.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 514
container_issue
container_start_page 502
container_title European journal of medicinal chemistry
container_volume 86
creator Pavić, K.
Perković, I.
Cindrić, M.
Pranjić, M.
Martin-Kleiner, I.
Kralj, M.
Schols, D.
Hadjipavlou-Litina, D.
Katsori, A.-M.
Zorc, B.
description Novel primaquine semicarbazides 7a–l and ureas 9a–g with modified benzhydryl, trityl, phenyl or hydroxyalkyl substituents were prepared and evaluated for cytostatic and antioxidative activities. Two synthetic approaches for preparation of the title semicarbazides were applied, both having certain advantages. In the first approach, the products grew from the semicarbazide side and the primaquine residue entered the molecule the last. In the second approach, semicarbazide grew from the primaquine side. This method was more convenient for synthesis of a series of semicarbazides: various products could be obtained from the same precursor N-(4-((6-methoxyquinolin-8-yl)amino)pentyl)hydrazinecarbox-amide (10). Primaquine ureas 9a–f were prepared from primaquine benzotriazolide 8 and corresponding amines and urea 9g directly from primaquine and 4-chloro-3-(fluoromethyl)phenyl isocyanate. All primaquine semicarbazide derivatives showed either prominent cytostatic activity towards all the tested cell lines (benzhydryl or trityl derivatives 7a–e) or high selectivity towards MCF-7 cells (hydroxyalkyl derivatives 7h–l), with IC50 values in the low micromolar range. The highest selectivity exerted symmetric bisprimaquine derivative 7f, with an IC50 0.2 μM against MCF-7 cells and practically no activity against other seven tested cancer cell lines. Urea derivatives 9a–f were generally less active than their semicarbazide analogues, but still selective towards MCF-7 cells. Urea 9g with the similar structure to cytostatic drug sorafenib, was the most active urea derivative. Semicarbazides 7g and 10 showed the best antioxidative activity as measured by DPPH (64% at 20 min and 90% at 60 min), while urea derivatives 9a–g, especially 9d, and semicarbazides 7a–g with lipophilic substituents exerted better LP antioxidant activity. Both semicarbazides and ureas with methoxy or chloro benzhydryl substituents and high Clog P values showed significant LOX inhibition. A series of primaquine semicarbazides 7a–l and ureas 9a–g with benzhydryl, trityl, phenyl and hydroxyalkyl substituents were prepared and evaluated for cytostatic and antioxidative activities. [Display omitted] •Synthesis of aryl and hydroxyalkyl primaquine semicarbazides and ureas was presented.•Most compounds displayed potent cytostatic and antioxidative activity.•One hit displayed high selectivity towards MCF-7 cells.
doi_str_mv 10.1016/j.ejmech.2014.09.013
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1609098610</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0223523414008319</els_id><sourcerecordid>1609098610</sourcerecordid><originalsourceid>FETCH-LOGICAL-c362t-9302c70a1f156b7a4479f9c1cb3180accd36ffc35655d15c10a718464c71e67d3</originalsourceid><addsrcrecordid>eNp9UU1v1DAQtRAV3Rb-AUI-ciDpOE6chANSVbWAVMEBOFvOeKL1ksSt7SwNf6F_mrRbOHIa6el9aN5j7LWAXIBQZ7ucdiPhNi9AlDm0OQj5jG1ErZpMFlX5nG2gKGRWFbI8Zicx7gCgUgAv2HFRFSDrBjbs_ovf08AjjQ5N6MxvZylyM1k-BzKR-57fBDea29lNxH-5tOXdPPxcuAnLwH3g28UGf7eYFVtt5i4ml2aaUnzPvy1T2lJ08R3HJfmYTHL46G2m5PydsyuwJ25wPS4tL9lRb4ZIr57uKftxdfn94lN2_fXj54vz6wylKlLWSiiwBiN6UamuNmVZt32LAjspGjCIVqq-R1mpqrKiQgGmFk2pSqwFqdrKU_b24HsT_O1MMenRRaRhMBP5OWqhoIW2UQJWanmgYvAxBur1Yxth0QL0wwx6pw8z6IcZNLR6nWGVvXlKmLuR7D_R395XwocDgdY_946CjuhoQrIuECZtvft_wh8MMZ5d</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1609098610</pqid></control><display><type>article</type><title>Novel semicarbazides and ureas of primaquine with bulky aryl or hydroxyalkyl substituents: Synthesis, cytostatic and antioxidative activity</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Pavić, K. ; Perković, I. ; Cindrić, M. ; Pranjić, M. ; Martin-Kleiner, I. ; Kralj, M. ; Schols, D. ; Hadjipavlou-Litina, D. ; Katsori, A.-M. ; Zorc, B.</creator><creatorcontrib>Pavić, K. ; Perković, I. ; Cindrić, M. ; Pranjić, M. ; Martin-Kleiner, I. ; Kralj, M. ; Schols, D. ; Hadjipavlou-Litina, D. ; Katsori, A.-M. ; Zorc, B.</creatorcontrib><description>Novel primaquine semicarbazides 7a–l and ureas 9a–g with modified benzhydryl, trityl, phenyl or hydroxyalkyl substituents were prepared and evaluated for cytostatic and antioxidative activities. Two synthetic approaches for preparation of the title semicarbazides were applied, both having certain advantages. In the first approach, the products grew from the semicarbazide side and the primaquine residue entered the molecule the last. In the second approach, semicarbazide grew from the primaquine side. This method was more convenient for synthesis of a series of semicarbazides: various products could be obtained from the same precursor N-(4-((6-methoxyquinolin-8-yl)amino)pentyl)hydrazinecarbox-amide (10). Primaquine ureas 9a–f were prepared from primaquine benzotriazolide 8 and corresponding amines and urea 9g directly from primaquine and 4-chloro-3-(fluoromethyl)phenyl isocyanate. All primaquine semicarbazide derivatives showed either prominent cytostatic activity towards all the tested cell lines (benzhydryl or trityl derivatives 7a–e) or high selectivity towards MCF-7 cells (hydroxyalkyl derivatives 7h–l), with IC50 values in the low micromolar range. The highest selectivity exerted symmetric bisprimaquine derivative 7f, with an IC50 0.2 μM against MCF-7 cells and practically no activity against other seven tested cancer cell lines. Urea derivatives 9a–f were generally less active than their semicarbazide analogues, but still selective towards MCF-7 cells. Urea 9g with the similar structure to cytostatic drug sorafenib, was the most active urea derivative. Semicarbazides 7g and 10 showed the best antioxidative activity as measured by DPPH (64% at 20 min and 90% at 60 min), while urea derivatives 9a–g, especially 9d, and semicarbazides 7a–g with lipophilic substituents exerted better LP antioxidant activity. Both semicarbazides and ureas with methoxy or chloro benzhydryl substituents and high Clog P values showed significant LOX inhibition. A series of primaquine semicarbazides 7a–l and ureas 9a–g with benzhydryl, trityl, phenyl and hydroxyalkyl substituents were prepared and evaluated for cytostatic and antioxidative activities. [Display omitted] •Synthesis of aryl and hydroxyalkyl primaquine semicarbazides and ureas was presented.•Most compounds displayed potent cytostatic and antioxidative activity.•One hit displayed high selectivity towards MCF-7 cells.</description><identifier>ISSN: 0223-5234</identifier><identifier>EISSN: 1768-3254</identifier><identifier>DOI: 10.1016/j.ejmech.2014.09.013</identifier><identifier>PMID: 25203780</identifier><language>eng</language><publisher>France: Elsevier Masson SAS</publisher><subject>Antineoplastic Agents - chemical synthesis ; Antineoplastic Agents - chemistry ; Antineoplastic Agents - pharmacology ; Antioxidants - chemical synthesis ; Antioxidants - chemistry ; Antioxidants - pharmacology ; Antioxidative activity ; Cell Line, Tumor ; Cell Proliferation - drug effects ; Cytostatic activity ; Cytostatic Agents - chemical synthesis ; Cytostatic Agents - chemistry ; Cytostatic Agents - pharmacology ; Dose-Response Relationship, Drug ; Drug Screening Assays, Antitumor ; HeLa Cells ; Humans ; MCF-7 Cells ; Molecular Structure ; Primaquine ; Primaquine - analogs &amp; derivatives ; Primaquine - chemical synthesis ; Primaquine - chemistry ; Primaquine - pharmacology ; Semicarbazide ; Semicarbazides - chemistry ; Semicarbazides - pharmacology ; Structure-Activity Relationship ; Urea ; Urea - analogs &amp; derivatives ; Urea - chemistry ; Urea - pharmacology</subject><ispartof>European journal of medicinal chemistry, 2014-10, Vol.86, p.502-514</ispartof><rights>2014 Elsevier Masson SAS</rights><rights>Copyright © 2014 Elsevier Masson SAS. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c362t-9302c70a1f156b7a4479f9c1cb3180accd36ffc35655d15c10a718464c71e67d3</citedby><cites>FETCH-LOGICAL-c362t-9302c70a1f156b7a4479f9c1cb3180accd36ffc35655d15c10a718464c71e67d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ejmech.2014.09.013$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3541,27915,27916,45986</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25203780$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pavić, K.</creatorcontrib><creatorcontrib>Perković, I.</creatorcontrib><creatorcontrib>Cindrić, M.</creatorcontrib><creatorcontrib>Pranjić, M.</creatorcontrib><creatorcontrib>Martin-Kleiner, I.</creatorcontrib><creatorcontrib>Kralj, M.</creatorcontrib><creatorcontrib>Schols, D.</creatorcontrib><creatorcontrib>Hadjipavlou-Litina, D.</creatorcontrib><creatorcontrib>Katsori, A.-M.</creatorcontrib><creatorcontrib>Zorc, B.</creatorcontrib><title>Novel semicarbazides and ureas of primaquine with bulky aryl or hydroxyalkyl substituents: Synthesis, cytostatic and antioxidative activity</title><title>European journal of medicinal chemistry</title><addtitle>Eur J Med Chem</addtitle><description>Novel primaquine semicarbazides 7a–l and ureas 9a–g with modified benzhydryl, trityl, phenyl or hydroxyalkyl substituents were prepared and evaluated for cytostatic and antioxidative activities. Two synthetic approaches for preparation of the title semicarbazides were applied, both having certain advantages. In the first approach, the products grew from the semicarbazide side and the primaquine residue entered the molecule the last. In the second approach, semicarbazide grew from the primaquine side. This method was more convenient for synthesis of a series of semicarbazides: various products could be obtained from the same precursor N-(4-((6-methoxyquinolin-8-yl)amino)pentyl)hydrazinecarbox-amide (10). Primaquine ureas 9a–f were prepared from primaquine benzotriazolide 8 and corresponding amines and urea 9g directly from primaquine and 4-chloro-3-(fluoromethyl)phenyl isocyanate. All primaquine semicarbazide derivatives showed either prominent cytostatic activity towards all the tested cell lines (benzhydryl or trityl derivatives 7a–e) or high selectivity towards MCF-7 cells (hydroxyalkyl derivatives 7h–l), with IC50 values in the low micromolar range. The highest selectivity exerted symmetric bisprimaquine derivative 7f, with an IC50 0.2 μM against MCF-7 cells and practically no activity against other seven tested cancer cell lines. Urea derivatives 9a–f were generally less active than their semicarbazide analogues, but still selective towards MCF-7 cells. Urea 9g with the similar structure to cytostatic drug sorafenib, was the most active urea derivative. Semicarbazides 7g and 10 showed the best antioxidative activity as measured by DPPH (64% at 20 min and 90% at 60 min), while urea derivatives 9a–g, especially 9d, and semicarbazides 7a–g with lipophilic substituents exerted better LP antioxidant activity. Both semicarbazides and ureas with methoxy or chloro benzhydryl substituents and high Clog P values showed significant LOX inhibition. A series of primaquine semicarbazides 7a–l and ureas 9a–g with benzhydryl, trityl, phenyl and hydroxyalkyl substituents were prepared and evaluated for cytostatic and antioxidative activities. [Display omitted] •Synthesis of aryl and hydroxyalkyl primaquine semicarbazides and ureas was presented.•Most compounds displayed potent cytostatic and antioxidative activity.•One hit displayed high selectivity towards MCF-7 cells.</description><subject>Antineoplastic Agents - chemical synthesis</subject><subject>Antineoplastic Agents - chemistry</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antioxidants - chemical synthesis</subject><subject>Antioxidants - chemistry</subject><subject>Antioxidants - pharmacology</subject><subject>Antioxidative activity</subject><subject>Cell Line, Tumor</subject><subject>Cell Proliferation - drug effects</subject><subject>Cytostatic activity</subject><subject>Cytostatic Agents - chemical synthesis</subject><subject>Cytostatic Agents - chemistry</subject><subject>Cytostatic Agents - pharmacology</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Screening Assays, Antitumor</subject><subject>HeLa Cells</subject><subject>Humans</subject><subject>MCF-7 Cells</subject><subject>Molecular Structure</subject><subject>Primaquine</subject><subject>Primaquine - analogs &amp; derivatives</subject><subject>Primaquine - chemical synthesis</subject><subject>Primaquine - chemistry</subject><subject>Primaquine - pharmacology</subject><subject>Semicarbazide</subject><subject>Semicarbazides - chemistry</subject><subject>Semicarbazides - pharmacology</subject><subject>Structure-Activity Relationship</subject><subject>Urea</subject><subject>Urea - analogs &amp; derivatives</subject><subject>Urea - chemistry</subject><subject>Urea - pharmacology</subject><issn>0223-5234</issn><issn>1768-3254</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UU1v1DAQtRAV3Rb-AUI-ciDpOE6chANSVbWAVMEBOFvOeKL1ksSt7SwNf6F_mrRbOHIa6el9aN5j7LWAXIBQZ7ucdiPhNi9AlDm0OQj5jG1ErZpMFlX5nG2gKGRWFbI8Zicx7gCgUgAv2HFRFSDrBjbs_ovf08AjjQ5N6MxvZylyM1k-BzKR-57fBDea29lNxH-5tOXdPPxcuAnLwH3g28UGf7eYFVtt5i4ml2aaUnzPvy1T2lJ08R3HJfmYTHL46G2m5PydsyuwJ25wPS4tL9lRb4ZIr57uKftxdfn94lN2_fXj54vz6wylKlLWSiiwBiN6UamuNmVZt32LAjspGjCIVqq-R1mpqrKiQgGmFk2pSqwFqdrKU_b24HsT_O1MMenRRaRhMBP5OWqhoIW2UQJWanmgYvAxBur1Yxth0QL0wwx6pw8z6IcZNLR6nWGVvXlKmLuR7D_R395XwocDgdY_946CjuhoQrIuECZtvft_wh8MMZ5d</recordid><startdate>20141030</startdate><enddate>20141030</enddate><creator>Pavić, K.</creator><creator>Perković, I.</creator><creator>Cindrić, M.</creator><creator>Pranjić, M.</creator><creator>Martin-Kleiner, I.</creator><creator>Kralj, M.</creator><creator>Schols, D.</creator><creator>Hadjipavlou-Litina, D.</creator><creator>Katsori, A.-M.</creator><creator>Zorc, B.</creator><general>Elsevier Masson SAS</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20141030</creationdate><title>Novel semicarbazides and ureas of primaquine with bulky aryl or hydroxyalkyl substituents: Synthesis, cytostatic and antioxidative activity</title><author>Pavić, K. ; Perković, I. ; Cindrić, M. ; Pranjić, M. ; Martin-Kleiner, I. ; Kralj, M. ; Schols, D. ; Hadjipavlou-Litina, D. ; Katsori, A.-M. ; Zorc, B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c362t-9302c70a1f156b7a4479f9c1cb3180accd36ffc35655d15c10a718464c71e67d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Antineoplastic Agents - chemical synthesis</topic><topic>Antineoplastic Agents - chemistry</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antioxidants - chemical synthesis</topic><topic>Antioxidants - chemistry</topic><topic>Antioxidants - pharmacology</topic><topic>Antioxidative activity</topic><topic>Cell Line, Tumor</topic><topic>Cell Proliferation - drug effects</topic><topic>Cytostatic activity</topic><topic>Cytostatic Agents - chemical synthesis</topic><topic>Cytostatic Agents - chemistry</topic><topic>Cytostatic Agents - pharmacology</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Screening Assays, Antitumor</topic><topic>HeLa Cells</topic><topic>Humans</topic><topic>MCF-7 Cells</topic><topic>Molecular Structure</topic><topic>Primaquine</topic><topic>Primaquine - analogs &amp; derivatives</topic><topic>Primaquine - chemical synthesis</topic><topic>Primaquine - chemistry</topic><topic>Primaquine - pharmacology</topic><topic>Semicarbazide</topic><topic>Semicarbazides - chemistry</topic><topic>Semicarbazides - pharmacology</topic><topic>Structure-Activity Relationship</topic><topic>Urea</topic><topic>Urea - analogs &amp; derivatives</topic><topic>Urea - chemistry</topic><topic>Urea - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pavić, K.</creatorcontrib><creatorcontrib>Perković, I.</creatorcontrib><creatorcontrib>Cindrić, M.</creatorcontrib><creatorcontrib>Pranjić, M.</creatorcontrib><creatorcontrib>Martin-Kleiner, I.</creatorcontrib><creatorcontrib>Kralj, M.</creatorcontrib><creatorcontrib>Schols, D.</creatorcontrib><creatorcontrib>Hadjipavlou-Litina, D.</creatorcontrib><creatorcontrib>Katsori, A.-M.</creatorcontrib><creatorcontrib>Zorc, B.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pavić, K.</au><au>Perković, I.</au><au>Cindrić, M.</au><au>Pranjić, M.</au><au>Martin-Kleiner, I.</au><au>Kralj, M.</au><au>Schols, D.</au><au>Hadjipavlou-Litina, D.</au><au>Katsori, A.-M.</au><au>Zorc, B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Novel semicarbazides and ureas of primaquine with bulky aryl or hydroxyalkyl substituents: Synthesis, cytostatic and antioxidative activity</atitle><jtitle>European journal of medicinal chemistry</jtitle><addtitle>Eur J Med Chem</addtitle><date>2014-10-30</date><risdate>2014</risdate><volume>86</volume><spage>502</spage><epage>514</epage><pages>502-514</pages><issn>0223-5234</issn><eissn>1768-3254</eissn><abstract>Novel primaquine semicarbazides 7a–l and ureas 9a–g with modified benzhydryl, trityl, phenyl or hydroxyalkyl substituents were prepared and evaluated for cytostatic and antioxidative activities. Two synthetic approaches for preparation of the title semicarbazides were applied, both having certain advantages. In the first approach, the products grew from the semicarbazide side and the primaquine residue entered the molecule the last. In the second approach, semicarbazide grew from the primaquine side. This method was more convenient for synthesis of a series of semicarbazides: various products could be obtained from the same precursor N-(4-((6-methoxyquinolin-8-yl)amino)pentyl)hydrazinecarbox-amide (10). Primaquine ureas 9a–f were prepared from primaquine benzotriazolide 8 and corresponding amines and urea 9g directly from primaquine and 4-chloro-3-(fluoromethyl)phenyl isocyanate. All primaquine semicarbazide derivatives showed either prominent cytostatic activity towards all the tested cell lines (benzhydryl or trityl derivatives 7a–e) or high selectivity towards MCF-7 cells (hydroxyalkyl derivatives 7h–l), with IC50 values in the low micromolar range. The highest selectivity exerted symmetric bisprimaquine derivative 7f, with an IC50 0.2 μM against MCF-7 cells and practically no activity against other seven tested cancer cell lines. Urea derivatives 9a–f were generally less active than their semicarbazide analogues, but still selective towards MCF-7 cells. Urea 9g with the similar structure to cytostatic drug sorafenib, was the most active urea derivative. Semicarbazides 7g and 10 showed the best antioxidative activity as measured by DPPH (64% at 20 min and 90% at 60 min), while urea derivatives 9a–g, especially 9d, and semicarbazides 7a–g with lipophilic substituents exerted better LP antioxidant activity. Both semicarbazides and ureas with methoxy or chloro benzhydryl substituents and high Clog P values showed significant LOX inhibition. A series of primaquine semicarbazides 7a–l and ureas 9a–g with benzhydryl, trityl, phenyl and hydroxyalkyl substituents were prepared and evaluated for cytostatic and antioxidative activities. [Display omitted] •Synthesis of aryl and hydroxyalkyl primaquine semicarbazides and ureas was presented.•Most compounds displayed potent cytostatic and antioxidative activity.•One hit displayed high selectivity towards MCF-7 cells.</abstract><cop>France</cop><pub>Elsevier Masson SAS</pub><pmid>25203780</pmid><doi>10.1016/j.ejmech.2014.09.013</doi><tpages>13</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0223-5234
ispartof European journal of medicinal chemistry, 2014-10, Vol.86, p.502-514
issn 0223-5234
1768-3254
language eng
recordid cdi_proquest_miscellaneous_1609098610
source MEDLINE; ScienceDirect Journals (5 years ago - present)
subjects Antineoplastic Agents - chemical synthesis
Antineoplastic Agents - chemistry
Antineoplastic Agents - pharmacology
Antioxidants - chemical synthesis
Antioxidants - chemistry
Antioxidants - pharmacology
Antioxidative activity
Cell Line, Tumor
Cell Proliferation - drug effects
Cytostatic activity
Cytostatic Agents - chemical synthesis
Cytostatic Agents - chemistry
Cytostatic Agents - pharmacology
Dose-Response Relationship, Drug
Drug Screening Assays, Antitumor
HeLa Cells
Humans
MCF-7 Cells
Molecular Structure
Primaquine
Primaquine - analogs & derivatives
Primaquine - chemical synthesis
Primaquine - chemistry
Primaquine - pharmacology
Semicarbazide
Semicarbazides - chemistry
Semicarbazides - pharmacology
Structure-Activity Relationship
Urea
Urea - analogs & derivatives
Urea - chemistry
Urea - pharmacology
title Novel semicarbazides and ureas of primaquine with bulky aryl or hydroxyalkyl substituents: Synthesis, cytostatic and antioxidative activity
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T03%3A30%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Novel%20semicarbazides%20and%20ureas%20of%20primaquine%20with%20bulky%20aryl%20or%20hydroxyalkyl%20substituents:%20Synthesis,%20cytostatic%20and%20antioxidative%20activity&rft.jtitle=European%20journal%20of%20medicinal%20chemistry&rft.au=Pavi%C4%87,%20K.&rft.date=2014-10-30&rft.volume=86&rft.spage=502&rft.epage=514&rft.pages=502-514&rft.issn=0223-5234&rft.eissn=1768-3254&rft_id=info:doi/10.1016/j.ejmech.2014.09.013&rft_dat=%3Cproquest_cross%3E1609098610%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1609098610&rft_id=info:pmid/25203780&rft_els_id=S0223523414008319&rfr_iscdi=true